Investment Analysts’ Recent Ratings Changes for Stryker (SYK)

Several analysts have recently updated their ratings and price targets for Stryker (NYSE: SYK):

• 5/16/2026 – Stryker was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/4/2026 – Stryker was downgraded by Weiss Ratings from “hold (c+)” to “hold (c)”.
• 5/4/2026 – Stryker had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $330.00 price target on the stock, down from $380.00.
• 5/4/2026 – Stryker had its price target lowered by Barclays PLC from $469.00 to $394.00. They now have an “overweight” rating on the stock.
• 5/2/2026 – Stryker was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/1/2026 – Stryker had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $361.00 price target on the stock.
• 5/1/2026 – Stryker was given a new $410.00 price target by Sanford C. Bernstein.
• 5/1/2026 – Stryker was given a new $385.00 price target by Robert W. Baird.
• 5/1/2026 – Stryker was given a new $355.00 price target by Evercore Inc.
• 5/1/2026 – Stryker was given a new $315.00 price target by Deutsche Bank Aktiengesellschaft.
• 5/1/2026 – Stryker had its price target lowered by Canaccord Genuity Group Inc. from $435.00 to $400.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Stryker had its price target lowered by JPMorgan Chase & Co. from $445.00 to $400.00. They now have an “overweight” rating on the stock.
• 5/1/2026 – Stryker had its price target lowered by Wells Fargo & Company from $456.00 to $418.00. They now have an “overweight” rating on the stock.
• 5/1/2026 – Stryker had its price target lowered by BTIG Research from $397.00 to $379.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Stryker had its price target lowered by Needham & Company LLC from $454.00 to $418.00. They now have a “buy” rating on the stock.
• 4/18/2026 – Stryker was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/15/2026 – Stryker had its price target lowered by Truist Financial Corporation from $395.00 to $380.00. They now have a “hold” rating on the stock.
• 4/14/2026 – Stryker had its “buy” rating reaffirmed by BTIG Research. They now have a $397.00 price target on the stock.
• 4/13/2026 – Stryker is now covered by Leerink Partners. They set an “outperform” rating and a $410.00 price target on the stock.
• 4/9/2026 – Stryker had its price target lowered by The Goldman Sachs Group, Inc. from $403.00 to $357.00. They now have a “neutral” rating on the stock.
• 4/7/2026 – Stryker had its price target lowered by Citigroup Inc. from $420.00 to $385.00. They now have a “buy” rating on the stock.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.60% of the company’s stock.

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.